Aflac (AFL) is experiencing a shifting valuation narrative as analysts adjust their earnings and price target models based on the latest market conditions. The modelled fair value remains anchored at $113.0, while analyst price targets cluster in a range from approximately $101 to $120. This narrow band reflects a divergence between bullish views emphasizing capital strength and earnings potential and more cautious perspectives highlighting sector headwinds and reduced earnings per share (EPS) estimates. Specifically, Wells Fargo lifted its price target to $118 while maintaining an Equal Weight rating, extending its EPS frameworks to 2028, whereas Bank of America trimmed its target to $120 but kept a Buy rating. Conversely, Barclays lowered its target to $101 with an Equal Weight, citing concerns over spread compression and increased technology spending that could impact profitability across the life insurance sector. Operational updates from Aflac further contextuaize its financial position, including new reinsurance agreements and product enhancements. Aflac Re Bermuda Ltd agreed to reinsure a block of whole life annuities from Japan Post Insurance effective March 31, 2026, with Japan Post continuing policy administration. Additionally, the company added a long-term care rider to its Group Life Term to 120 product targeting aging-related costs, and entered into an affiliation with Empower Brokerage, enabling over 8,000 agents to sell its products. Significant capital management is evident in recent share repurchases; from October 1, 2025, to December 31, 2025, Aflac purchased 7,249,599 shares for $800.12 million, bringing total authorized buybacks to approximately 41.51% of the outstanding share count valued at over $17.6 billion. Underlying financial assumptions driving the Simply Wall St valuation model remain largely consistent with prior estimates. Revenue growth input is set at 1.53%, net profit margin is held at around 21.14%, and future P/E multiples are maintained at approximately 16.36x, with no adjustment to the discount rate of roughly 6.978%. While the company aims to widen its customer base through product changes like the Miraito cancer policy and expanded dental offerings, it faces key risks that could pressure margins and future earnings. These include Japan premium trends, higher technology and expense ratios, currency exposure, and slower U.S. sales growth. Analysts note a general trend of reducing EPS estimates for the group as companies update guidance, indicating that Aflac's earnings path is being reassessed despite stable valuation metrics.